Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does HSBC (HSBC) have what it takes? Let's find out.
While Peloton (PTON) shares were raised to a Buy rating by Truist analysts, Wall Street is eyeing streaming platform Spotify's (SPOT) advertising business performance ahead of its first quarter earnings report tomorrow, Tuesday, April 29. Wealth host Brad Smith and Yahoo Finance senior reporter Alexandra Canal talk more about these stocks trending on the Yahoo Finance platform. To watch more expert insights and analysis on the latest market action, check out more Wealth here.
Technology stocks were a big drag on the S&P 500 to start the day on Monday. The market benchmark was down 0.6% after hovering around breakeven for much of the morning, but more than half of the stocks in the index were actually trading higher.
Electrical equipment maker Schneider Electric cut its 2025 implied core profit margin outlook on Monday due to the impact of foreign exchange rates, after its sales missed market expectations in the first quarter. Schneider Electric, which develops AI-related data centre cooling systems, now sees 2025 adjusted earnings before interest, taxes and amortization (EBITA) margin between 18.7% and 19%, compared with its previous core profit margin expectation of between 19.2% and 19.5%.
We recently published a list of Top 10 Stocks to Watch as Investors Brace for Recession. In this article, we are going to take a look at where Boeing Co (NYSE:BA) stands against other top stocks to watch as investors brace for recession. Despite some optimism in the market after President Donald Trump’s indication of […]
We recently compiled a list of the 12 Best Nickel Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Leggett & Platt, Incorporated (NYSE:LEG) stands against the other nickel stocks. Nickel is a metal that is used extensively in manufacturing. It is a key component of […]
CG Oncology, Inc. (NASDAQ:CGON) announced on Saturday that cretostimogene grenadenorepvec monotherapy data were presented at the 2025 American Urological Association Annual Meeting. The Phase 3 BOND-003 Cohort C study is in patients with high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) treatment with carcinoma in situ (CIS) with or without Ta or T1 disease. The study reported 75.5% complete response (CR) at any time, with 34 confirmed CRs at 24